Danoprevir improved SVR rate from peginterferon/ribavirin therapy in HCV patients
Patients with hepatitis C genotype 1 treated with danoprevir in
addition to pegylated interferon and ribavirin experienced high rates of
sustained virologic response, but high danoprevir doses were linked to
severe ALT increases in a recent study.
In a phase 2, international, parallel-group study, researchers randomly assigned 237 treatment-naive adult patients with hepatitis C
genotype 1 to peginterferon alfa-2a and weight-based ribavirin with
either placebo (n=31) or 12 weeks of danoprevir administered at 300 mg
every 8 hours (n=72), 600 mg every 12 hours (n=72) or 900 mg every 12
hours (n=50) for 12 weeks. Treatment was followed by
peginterferon/ribavirin alone for 48 weeks. If extended rapid virologic
response occurred (eRVR; HCV RNA below 15 IU/mL from weeks 4 through
20), treatment was stopped at 24 weeks.
Treating HCV genotypes 2 and 3 in HIV/HCV co-infected people
People co-infected with HIV and HCV, mostly with hepatitis C
virus (HCV) genotype 3, responded about as well as HIV-negative people to interferon-based
therapy after taking into account other factors associated with poor treatment response,
according to an Italian study presented at the 53rd Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC)
this month in Denver. Advanced liver fibrosis was common in the co-infected
group, supporting the need for early treatment.
An estimated one-third of HIV-positive people are
co-infected with HCV, with higher rates in countries where the HIV epidemic is
largely driven by injecting drug use. Over years or decades, chronic hepatitis C
can lead to serious liver disease, including advanced fibrosis, cirrhosis and
hepatocellular carcinoma. HIV/HCV co-infected people tend to experience faster
liver disease progression and do not respond as well to interferon as people
with HCV alone.
The View from the Frontlines: The status of HCV-monoinfected persons in Canada, presented at the CATIE 2013 conference, by Cheryl Reitz
Cheryl Reitz, a volunteer with HepCBC recently spoke at the Canadian AIDS Treatment Information Exchange Conference (CATIE) in Toronto, Canada, highlighting the disparities affecting HCV-monoinfected persons in Canada.
‘Tainted’ tells story of Canada’s blood scandal through affected family’s eyes
“Tainted,” a play debuting Wednesday in Toronto, recalls the tragic
events through the eyes of a family with three hemophiliac sons who
discover they have contracted both deadly diseases from the clotting
factor made from contaminated blood.
TORONTO – It’s been called one of the worst public health crises in
Canadian history — the contaminated blood scandal that left more than
1,000 Canadians infected with HIV and another 30,000 with hepatitis C.
Some contracted both.
The majority were hemophiliacs who had been
given blood products meant to save their lives, but the treatment turned
out to be a death warrant not only for many of them, but also for loved
ones whom they unwittingly infected.
CDC: Hepatitis A Outbreak Now at 162 Cases in 10 States
The Centers for Disease Control and Prevention issued an update Monday
reporting that the number of Hepatitis A cases associated with Townsend
Farms Organic Antioxidant Blend now totals 162, with 71 people having
been hospitalized. No deaths have been reported.
The cases were reported in 10 states: Arizona, California, Colorado,
Hawaii, New Hampshire, New Jersey, New Mexico, Nevada, Utah and
Wisconsin. CDC notes that the cases reported from Wisconsin resulted
from exposure to the Townsend Farms product in California, the cases
reported from New Hampshire reported exposure during travel to Nevada,
and the case reported in New Jersey was a household contact from a
confirmed case from Colorado.